A new blood test could end the need for invasive, potentially risky post-transplant biopsies taken regularly after heart transplant surgery to monitor the possibility of organ rejection. The AlloMap blood test, which compared positively to more than 600 heart transplant biopsies, could become a simple alternative to this procedure and could allow patients to be monitored from many miles away.

Related Summaries